TNA Therapeutics is focused on developing innovative small molecule inhibitors, particularly their lead compound TNAT-101, which targets the novel protein BCL3. This transcriptional regulator is crucial in various cancer-related processes, including tumor growth, metastasis, and the viability of cancer stem cells. By inhibiting BCL3, TNAT-101 aims to disrupt critical signaling pathways that contribute to cancer initiation and progression, thereby providing a potential treatment for patients with rare and difficult-to-treat cancers, such as colorectal cancer (CRC) and triple-negative breast cancer (TNBC). The compound has shown promising preclinical efficacy, demonstrating significant anti-metastatic effects and improvements in survival rates in various cancer models.

The development of TNAT-101 has been supported by advanced molecular modeling techniques that optimize its interaction with BCL3 and its partners, p50 and p52. The compound has undergone extensive preclinical safety assessments, indicating it is well tolerated at doses significantly higher than those effective in animal models. TNA Therapeutics is committed to addressing the unmet medical needs in oncology by not only targeting primary tumors but also focusing on preventing metastasis and recurrence, which are critical factors in improving long-term patient outcomes. The broader implications of BCL3 inhibition suggest potential applications across multiple cancer types, reinforcing the significance of TNAT-101 in the future of cancer therapeutics.

United Kingdom

We are developing cancer treatments that specifically target the cancer stem cell population in tumors. Targeting these cells will prevent relapse and disease progression leading to long-term patient benefit.

TNA Therapeutics

Company Details